Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse
AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
Alopecia Areata An autoimmune disease that causes inflammation at the hair follicle[1,3] 
  • Loss of hair follicle immune privilege leads to infiltration of the immune system, such as CD8+ cells, T cells, and NK cells, into and around the hair bulb in a pattern referred to as the swarm of bees[4] 
  • Inflammatory cytokines are released during the activation and proliferation of immune cells, contributing to a cycle of sustained inflammation and follicle dystrophy that results in hair loss[4-6] 
  • Activation of the JAK3 and the TEC kinase family of enzymes may be involved in the inflammatory response, resulting in hair loss in alopecia areata[6-8] 
For patients with alopecia areata, there remains a need for more treatment options[9] 
  • Patients with 50% or more scalp hair loss have low spontaneous remission rates (~5%)[10] 
  • Up to 36.1% of patients with alopecia areata are at risk of developing alopecia totalis or alopecia universalis[10]
  • Alopecia areata can occur at any age and affects both children and adults[10,14] 
  • Loss of eyebrows and/or eyelashes due to alopecia areata may result in eye irritation[14] 
 Learn how LITFULO works LITFULO mechanism of action LoadingCD8+=cluster of differentiation 8 positive; JAK=Janus kinase; NK=natural killer; TEC=tyrosine kinase expressed in hepatocellular carcinoma.ReferencesReferences:1.Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015,14(2):81-89. doi:10.1016/j.autrev.2014.10.014 3.Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299-312. 4.Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013;2013:348546. doi:10.1155/2013/348546 5.Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nat Med. 2014;20(9):989-990. doi:10.1038/nm.3685 6.Passeron T, King B, Seneschal J, Steinhoff M, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556. doi:10.3389/fimmu.2023.1243556 7.Xu H, Jesson MI, Seneviratne Ul, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6);1235-1242. doi:10.1021/acschembio.9b00188 8.Schwartzberg PL, Finkelstein LD, Readinger JA. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol. 2005;5(4):284-295. doi:10.1038/nri1591 9.Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol.2022;149(4):1318-1328. doi:10.1016/j.jaci.2021.10.036 10.Tosti A, Bellavista S, lorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438-441. doi:10.1016/j.jaad.2006.05.008 14.Wyrwich KW, Kitchen H, Knight S, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725-732. doi:10.1007/s40257-020-00545-9About See how LITFULO helped patients with severe alopecia areata EfficacyLoading Get appropriate patients started on LITFULO today Getting startedLoading
 Indication Litfulo® (ritlecitinib):
 Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.[Litfulo SmPC] 
 Litfulo pligttekst

Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

 

PfizerPro kontoPfizerPro konto

Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

Log indRegisterMin profilLog ud

Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

 

© Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

12 August 2025 * PP-LGF-DNK-0008
Du forlader nu Pfizer
Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.